Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company’s shares closed yesterday at $11.64. According to TipRanks, Werber is a 5-star ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These ...

Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...

Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...

Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...